Mineralys Therapeutics, Common Stock Alpha and Beta Analysis
| MLYS Stock | 11.87 0.73 5.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mineralys Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mineralys Therapeutics, over a specified time horizon. Remember, high Mineralys Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mineralys Therapeutics,'s market risk premium analysis include:
Beta 2.57 | Alpha 0.11 | Risk 3.78 | Sharpe Ratio 0.0121 | Expected Return 0.0456 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Mineralys |
Mineralys Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mineralys Therapeutics, market risk premium is the additional return an investor will receive from holding Mineralys Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mineralys Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mineralys Therapeutics,'s performance over market.| α | 0.11 | β | 2.57 |
Mineralys Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Mineralys Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Mineralys Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Mineralys Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Mineralys Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mineralys Therapeutics, shares will generate the highest return on investment. By understating and applying Mineralys Therapeutics, stock market price indicators, traders can identify Mineralys Therapeutics, position entry and exit signals to maximize returns.
Mineralys Therapeutics, Return and Market Media
The median price of Mineralys Therapeutics, for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 12.57 with a coefficient of variation of 8.27. The daily time series for the period is distributed with a sample standard deviation of 1.05, arithmetic mean of 12.72, and mean deviation of 0.94. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference | 08/28/2024 |
2 | Disposition of 5018 shares by Rodman David Malcom of Mineralys Therapeutics, at 0.54 subject to Rule 16b-3 | 09/11/2024 |
3 | Disposition of 10411846 shares by Hbm Healthcare Investments Ltd. of Mineralys Therapeutics, subject to Rule 16b-3 | 09/19/2024 |
4 | Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension | 09/25/2024 |
5 | Disposition of 15271 shares by Jon Congleton of Mineralys Therapeutics, at 13.518 subject to Rule 16b-3 | 10/11/2024 |
6 | Acquisition by Rodman David Malcom of 5352 shares of Mineralys Therapeutics, at 1.08 subject to Rule 16b-3 | 10/14/2024 |
7 | Mineralys Therapeutics CEO sells 206,433 in stock | 10/15/2024 |
8 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud | 10/22/2024 |
9 | Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm | 10/25/2024 |
10 | Disposition of 25482 shares by Rodman David Malcom of Mineralys Therapeutics, at 15.0328 subject to Rule 16b-3 | 11/06/2024 |
11 | Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/11/2024 |
12 | Earnings call Mineralys Therapeutics reports Q3 2024 results, progress | 11/12/2024 |
About Mineralys Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mineralys or other stocks. Alpha measures the amount that position in Mineralys Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Current Ratio | 23.76 | 24.95 | Net Debt To EBITDA | 0.58 | 0.55 |
Mineralys Therapeutics, Upcoming Company Events
As portrayed in its financial statements, the presentation of Mineralys Therapeutics,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mineralys Therapeutics,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mineralys Therapeutics,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mineralys Therapeutics,. Please utilize our Beneish M Score to check the likelihood of Mineralys Therapeutics,'s management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Mineralys Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.